Guyer William sold $1.4M of CORT

Guyer William (Chief Development Officer) sold 20,000 shares of CORCEPT THERAPEUTICS INC (CORT) at $70.60 ($1.41M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Guyer William
Published Jun 4, 2026, 8:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider liquidity/diversification but does not introduce new operational, clinical, or regulatory information.

02

Market read

Traders may monitor for sentiment effects, but the 10b5-1 designation reduces the likelihood of a fundamental repricing catalyst.

03

What to watch

Insider sales can be driven by diversification/tax planning; without additional context (e.g., size vs. typical pattern), directional inference is weak.

Relevance 6/10Novelty 3/10Timing: Filed today; sale executed 2026-06-02 and disclosed 2026-06-04.

Background

SEC Form 4 insider transaction: open-market sale by an officer, executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics insider Chief Development Officer William Guyer sold 20,000 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Small, short-lived negative-to-neutral drift possible; no strong directional catalyst implied.

Evidence & confidence

The filing is a disclosed sale (not a purchase) but explicitly states a pre-arranged Rule 10b5-1 plan, which typically reduces interpretability as new negative information.

Market effects

Limited read-through for biotech/biopharma sector; this is company-specific insider activity without new clinical/regulatory data.

No clear regional spillover expected from a single Form 4 disclosure.

Minimal global relevance; disclosure is routine and not tied to a deal or regulatory action.

Counterpoint

Because the sale is under a 10b5-1 plan, the market may overreact; price may mean-revert if no other catalysts exist.

Key entities

  • Corcept Therapeutics Inc

    Subject of the Form 4 insider sale disclosure.

  • William Guyer

    Chief Development Officer who sold 20,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.